Novel Chemo Delivery System Achieves High Response Rate in Bladder Cancer
CHICAGO — An investigational intravesical delivery system designed to provide sustained local release of gemcitabine into the bladder produced high rates of complete response (CR) in difficult-to-treat non-muscle-invasive bladder cancer (NMIBC), data from an ongoing phase IIb study showed. Preliminary results from the SunRISe-1 trial demonstrated that monotherapy with the novel treatment, dubbed TAR-200, led […]
Sequential Gemcitabine/Docetaxel Promising in NMIBC After BCG Relapse
SAN DIEGO — The use of sequential intravesical gemcitabine and docetaxel appeared effective and well tolerated in patients with high-risk non-muscle invasive bladder cancer (NMIBC) following the failure of bacillus Calmette-Guérin (BCG) therapy, a retrospective study showed. At a median follow-up of 18 months, the 6-, 12-, and 24-month high-grade recurrence-free survival (RFS) rates among […]
Durable Responses With IL-15 Superagonist in Early Bladder Cancer
The use of the IL-15RAFC superagonist N-803 with intravesical bacillus Calmette-Guérin (BCG) resulted in high and more durable response rates in patients with non-muscle invasive bladder cancer (NMIBC) carcinoma in situ who were unresponsive to BCG, a phase II/III study found. Of the 81 patients included in the analysis, 58 achieved a complete response at […]